A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer
A phase 2 trial of Dostarlimab and Carboplatin in advanced solid tumours, run by GlaxoSmithKline, active and no longer recruiting.
Overview
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer is a phase 2 interventional study registered as NCT06317311 by GlaxoSmithKline, with 41 participants enrolled, started 2024-05-07 and due to reach its primary completion in 2026-07-15. Interventions recorded: Dostarlimab, Carboplatin and Paclitaxel.
Similar pages
not linked directly; found by shared links- TrialA Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
Shares Dostarlimab, GSK, Carboplatin and the tag pipeline.
- TrialA Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
Shares Dostarlimab, GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
Shares Dostarlimab, GSK and the tag pipeline.
- TrialA Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
Shares Dostarlimab, GSK and the tag pipeline.
- TrialA Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China
Shares Dostarlimab, GSK and the tag pipeline.
- TrialA Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
Shares Dostarlimab, GSK and the tag pipeline.
- TrialA Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Shares Dostarlimab, GSK and the tag pipeline.
- TrialA Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.